Lead Product(s) : DD01
Therapeutic Area : Hepatology (Liver, Pancreatic, Gall Bladder)
Study Phase : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
D&D Completes Enrollment for 48-Week Phase 2 Trial of DD01 in MASH Treatment
Details : DD01 is a proprietary, once-weekly dual agonist of GLP-1 (glucagon-like peptide-1) and glucagon receptors. It is being evaluated for the treatment of adults with non-alcoholic steatohepatitis.
Product Name : DD01
Product Type : Peptide
Upfront Cash : Inapplicable
February 03, 2025
Lead Product(s) : DD01
Therapeutic Area : Hepatology (Liver, Pancreatic, Gall Bladder)
Highest Development Status : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : DD01
Therapeutic Area : Hepatology (Liver, Pancreatic, Gall Bladder)
Study Phase : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
D&D Pharmatech Begins Dosing in Phase 2 Trial of DD01 for MASLD/MASH
Details : DD01 is a proprietary, once-weekly dual agonist of GLP-1 (glucagon-like peptide-1) and glucagon receptors. It is being evaluated for the treatment of adults with non-alcoholic steatohepatitis.
Product Name : DD01
Product Type : Peptide
Upfront Cash : Inapplicable
August 21, 2024
Lead Product(s) : DD01
Therapeutic Area : Hepatology (Liver, Pancreatic, Gall Bladder)
Highest Development Status : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : LB-P8
Therapeutic Area : Hepatology (Liver, Pancreatic, Gall Bladder)
Study Phase : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
LISCure Biosciences Receives FDA Fast Track Designation for LB-P8 for PSC Treatment
Details : LB-P8 is an investigational live biotherapeutic product consisting of a single bacterial strain (Leuconostoc citreum). It is being evaluated for the treatment of primary sclerosing cholangitis.
Product Name : LB-P8
Product Type : Microorganism
Upfront Cash : Inapplicable
March 29, 2024
Lead Product(s) : LB-P8
Therapeutic Area : Hepatology (Liver, Pancreatic, Gall Bladder)
Highest Development Status : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : HM15211
Therapeutic Area : Hepatology (Liver, Pancreatic, Gall Bladder)
Study Phase : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
FDA grants fast track status to Hanmi’s investigational fatty liver med
Details : The novel drug is under development with the company’s Lapscovery, a platform technology that prolongs the duration of action of biologics, making it possible for patients to take weekly or monthly administration.
Product Name : HM15211
Product Type : Peptide
Upfront Cash : Inapplicable
July 22, 2020
Lead Product(s) : HM15211
Therapeutic Area : Hepatology (Liver, Pancreatic, Gall Bladder)
Highest Development Status : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Efinopegdutide
Therapeutic Area : Hepatology (Liver, Pancreatic, Gall Bladder)
Study Phase : Phase II
Sponsor : Merck & Co
Deal Size : $870.0 million
Deal Type : Licensing Agreement
Merck and Hanmi Pharmaceutical Enter into Licensing Agreement to Develop Efinopegdutide
Details : Under the agreement, Merck will be granted an exclusive license to develop, manufacture and commercialize efinopegdutidein the United States and globally.
Product Name : HM12525A
Product Type : Peptide
Upfront Cash : $10.0 million
April 08, 2020
Lead Product(s) : Efinopegdutide
Therapeutic Area : Hepatology (Liver, Pancreatic, Gall Bladder)
Highest Development Status : Phase II
Sponsor : Merck & Co
Deal Size : $870.0 million
Deal Type : Licensing Agreement